Association between reproductive and hormonal factors and age-related maculopathy in postmenopausal women

American Journal of Ophthalmology

Volumn 134, Issue 6, 2002, Pages 842-848

  Snow, Kristin K ^a   Cote, Jennifer ^a   Yang, Weining ^a   Davis, Nancy J ^a   Seddon, Johanna M ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENARCHE; POSTMENOPAUSE; PRIORITY JOURNAL; REPRODUCTION; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR;

AGED; CONTRACEPTIVES, ORAL, HORMONAL; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MACULAR DEGENERATION; MASSACHUSETTS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; REGISTRIES; REPRODUCTIVE HISTORY; RISK FACTORS;

EID: 0036897357     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(02)01755-5     Document Type: Article

References (30)

1. Klein R., Klein B.E.K., Linton K.L.P. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 99:1992;933-943.
2. Segato T., Midena E., Blarzino M.C. Age-related macular degeneration. Aging. 5:1993;165-176.
3. Smith W., Mitchell P., Wang J.J. Gender, oestrogen, hormone replacement and age-related macular degeneration results from the Blue Mountains Eye Study. Aust N Z J Ophthalmol. 25:1997;S13-S15.
4. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol. 110:1992;1701-1708.
5. Klein B.E.K., Klein R., Jensen S.C., Ritter L.L. Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 92:1994;289-295.
6. Vingerling J.R., Dielemans I., Witteman J.C., Hofman A., Grobbee D.E., deJong P.T.V.M. Macular degeneration and early menopause a case-control study. BMJ. 310:1995;1570-1571.
7. Klein B.E.K., Klein R., Lee K.E. Reproductive exposures, incident age-related cataracts, and age-related maculopathy in women the Beaver Dam Eye Study. Am J Ophthalmol. 130:2000;322-326.
8. Snow K.K., Seddon J.M. Age-related eye diseases impact of hormone replacement therapy, and reproductive and other risk factors. Int J Fertil. 45:2000;301-313.
9. Age-Related Eye Disease Study (AREDS) phase II manual of operations. 1992;EMMES Corp, Potomac, MD.
10. Cohen J. Weighted kappa nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 70:1968;213-220.
11. Maltzman B.A., Mulvihill M.N., Greenbaum A. Senile macular degeneration and risk factors a case-control study. Ann Ophthalmol. 11:1979;1197-1201.
12. Klein B.E.K., Klein R., Lee K.E. Incidence of age-related cataract. The Beaver Dam Eye Study. Arch Ophthalmol. 116:1998;219-225.
13. Leske M.C., Wu S.-Y., Connell A.M.S., Hyman L., Schachat A.P. Lens opacities, demographic factors and nutritional supplements in the Barbados Eye Study. Int J Epidemiol. 26:1997;1314-1322.
14. Hirvela H., Luukinen H., Laatikainen L. Prevalence and risk factors of lens opacities in the elderly in Finland. A population-based study. Ophthalmology. 102:1995;108-117.
15. Klein B.E.K., Klein R. Cataracts and macular degeneration in older Americans. Arch Ophthalmol. 100:1982;571-573.
16. Risk factors for idiopathic macular holes. Am J Ophthalmol. 114:1994;545-554.
17. Risk factors for central retinal vein occlusion. Arch Ophthalmol. 114:1996;545-554.
18. Gray R.H., Gregor Z.J., Marsh M. Oestrogens and macular holes a postal questionnaire. Eye. 8:1994;368-369.
19. Calaf I., Alsina J. Benefits of hormone replacement therapy - overview and update. Int J Fertil. 42:1997;329-346.
20. Grodstein F., Stampfer M.J., Manson J.E., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 335:1996;453-461.
21. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 273:1995;199-208.
22. Grodstein F., Stampfer M.J., Colditz G.A., et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 336:1997;1769-1775.
23. Folsom A.R., Mink P.J., Sellers T.A., Hong C.-P., Zheng W., Potter J.D. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 85:1995;1128-1132.
24. Bass K.M., Newschaffer C.J., Klag M.J., Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 153:1993;2209-2216.
25. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., Barrett-Connor E. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation. 96:1997;2468-2482.
26. Subbiah M.T.R. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med. 217:1998;23-29.
27. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principal results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333.
28. Snow K.K., Seddon J.M. Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol. 6:1999;125-143.
29. Varga M. Recent experiences on the ophthalmologic complications of oral contraceptives. Ann Ophthalmol. 8:1976;925-934.
30. Vessey M.P., Hannaford P., Mant J., Painter R., Frith P., Chappel D. Oral contraception and eye disease findings in two large cohort studies. Br J Ophthalmol. 82:1998;538-542.